Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
Sponsor: Crucell Holland BV
Collaborators: U.S. National Institute of Allergy and Infectious Diseases Division of AIDS, U.S. Military HIV Research Program, Beth Israel Deaconess Medical Center, International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier: NCT02315703
USA; Rwanda; South Africa; Thailand; Uganda
Estimated  Enrollment: 400
Study Start Date:

December 2014